Cytokinetics (CYTK)
NASDAQ: CYTK
· Real-Time Price · USD
38.55
-0.17 (-0.44%)
At close: Aug 15, 2025, 12:49 PM
-0.44% (1D)
| Bid | 38.52 |
| Market Cap | 4.61B |
| Revenue (ttm) | 19.22M |
| Net Income (ttm) | -615.26M |
| EPS (ttm) | -5.12 |
| PE Ratio (ttm) | -7.53 |
| Forward PE | -6.48 |
| Analyst | Buy |
| Ask | 38.59 |
| Volume | 505,441 |
| Avg. Volume (20D) | 1,645,202.9 |
| Open | 38.92 |
| Previous Close | 38.72 |
| Day's Range | 37.79 - 39.10 |
| 52-Week Range | 29.31 - 59.39 |
| Beta | 0.65 |
About CYTK
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CYTK
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CYTK stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsEarnings Surprise
Cytokinetics has released their quartely earnings
on Aug 7, 2025:
Next Earnings Release
Cytokinetics is scheduled to release its earnings on
Nov 5, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
-12.98%
Cytokinetics shares are trading lower after the co...
Unlock content with
Pro Subscription
3 months ago
+0.19%
Cytokinetics shares are trading lower after the company announced the FDA has extended the Prescription Drug User Fee Act action date for Aficamten.
1 week ago · seekingalpha.com
Cytokinetics, Incorporated (CYTK) Q2 2025 Earnings Call TranscriptCytokinetics, Incorporated (NASDAQ:CYTK ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants & - Corporate Participant Andrew M. Callos - Executive VP & Chief Commercial O...
